We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Taysha Gene Therapies Inc (TSHA) USD0.00001

Sell:$3.35 Buy:$3.36 Change: $0.20 (6.17%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.20 (6.17%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.20 (6.17%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Taysha Gene Therapies, Inc. is a patient-centric gene therapy company. The Company is focused on developing and commercializing adeno-associated virus (AAV)-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS). Its portfolio of gene therapy candidates targets a range of neurological indications across three distinct therapeutic categories: neurodegenerative diseases, neurodevelopmental disorders, and genetic epilepsies. Its product candidates include TSHA-120, a clinical-stage, intrathecally dosed AAV9 gene therapy program for the treatment of giant axonal neuropathy (GAN); TSHA-102, a self-complementary intrathecally delivered AAV9 gene transfer therapy product candidate in clinical evaluation for Rett syndrome; TSHA-118, a self-complementary AAV9 viral vector that expresses human codon-optimized Ceroid Lipofuscinosis Neuronal 1 (CLN1) complementary deoxyribonucleic acid under control of the chicken b-actin hybrid promoter, and others.

Contact details

3000 Pegasus Park Drive, Suite 1430
United States
+1 (214) 6120000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$493.57 million
Shares in issue:
186.96 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Sean Nolan
    Chairman of the Board, Chief Executive Officer
  • Sukumar Nagendran
    President, Head of Research and Development, Director
  • Kamran Alam
    Chief Financial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.